Abstract
Inter-individual differences in genes for drug metabolising enzymes and drug transporters are important for understanding efficacy in drug therapy. These differences are important both for the timely estimation of the dosage that should be prescribed to a patient and for the detection of individuals who are prone to side effects from the drug at normal doses. This review summarises the literature concerning the gene variants within nine major drug metabolising enzymes and drug transporters (i.e., CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, and MDR-1) in the Middle European region. Notably, published data are not extensive, and most studies were performed on relatively low numbers of individuals. No country has a complete coverage of all genes. Two variants (C2677T/A and C3435T) within the multidrug resistance-1 (MDR-1) gene and variants within the CYP2C9 gene were analysed within most Slavic populations. Nevertheless, even from this incomplete coverage (where unexpectedly high variability was at times seen both between and within populations), it could be extrapolated that the variants within the drug metabolising enzyme genes are present in roughly the same frequencies as in neighbouring countries.
The author is supported by Ministry of Health, Czech Republic – conceptual development of research organisation (“Institute for Clinical and –Experimental Medicine – IKEM, IN 00023001“) and by IGA MZ CR projects NT/11307 – 5, NT/12170 – 5 and NT/12217 – 5.
Conflict of interest statement
Author conflict of interest disclosure: The author states that there are no conflict of interest regarding the publication of this article. Research support played no role in study design; in the collection, analysis, and interpretation of data; in writing the report; or in the decision to submit the report for publication.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Pereira NL, Weinshilboum RM. Cardiovascular pharmacogenomics and individualized drug therapy. Nat Rev Cardiol 2009;6:632–8.10.1038/nrcardio.2009.154Search in Google Scholar PubMed PubMed Central
2. Sanford JC, Guo Y, Sadee W, Wang D. Regulatory polymorphisms in CYP2C19 affecting hepatic expression. Drug Metabol Drug Interact 2013;28:23–30.10.1515/dmdi-2012-0038Search in Google Scholar PubMed PubMed Central
3. Meyer UA. Cytochrome P450 enzymes. Drug Metabol Drug Interact 2012;27:1–2.10.1515/dmdi-2012-0002Search in Google Scholar PubMed
4. Raunio H, Rahnasto-Rilla M. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact 2012;27: 73–88.10.1515/dmdi-2012-0001Search in Google Scholar PubMed
5. Małek LA, Przyłuski J, Spiewak M, Kłopotowski M, Kostrzewa G, Kruk M, et al. Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology 2010;117:81–7.10.1159/000320093Search in Google Scholar PubMed
6. Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, et al. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol 2012;68:1267–74.10.1007/s00228-012-1252-3Search in Google Scholar PubMed PubMed Central
7. Skrętkowicz J, Barańska M, Kaczorowska A, Rychlik-Sych M. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus. Arch Med Sci 2011;7:864–9.10.5114/aoms.2011.25563Search in Google Scholar PubMed PubMed Central
8. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 2005;574:112–23.10.1016/j.mrfmmm.2005.01.027Search in Google Scholar PubMed
9. Cichoz-Lach H, Celiński K, Słomka M. Alcohol-metabolizing enzyme gene polymorphisms and alcohol chronic pancreatitis among Polish individuals. HPB (Oxford) 2008;10:138–43.10.1080/13651820801938909Search in Google Scholar PubMed PubMed Central
10. Laczmanska I, Gil J, Karpinski P, Stembalska A, Kozlowska J, Busza H, et al. Influence of polymorphisms in xenobiotic-metabolizing genes and DNA-repair genes on diepoxybutane-induced SCE frequency. Environ Mol Mutagen 2006;47:666–73.10.1002/em.20253Search in Google Scholar PubMed
11. Żochowska D, Wyzgał J, Pączek L. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. Ann Transplant 2012;17:36–44.10.12659/AOT.883456Search in Google Scholar
12. Spiewak M, Małek ŁA, Kostrzewa G, Kisiel B, Serafin A, Filipiak KJ, et al. Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Kardiol Pol 2009;67:827–34.Search in Google Scholar
13. Buzková H, Pechandová K, Danzig V, Vařeka T, Perlík F, Žák A, et al. Lipid-lowering effect of fluvastatin in relation to the cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med Sci Monit 2012 2012;18:CR512–7.10.12659/MSM.883272Search in Google Scholar PubMed PubMed Central
14. Buzková H, Pechandová K, Slanař O, Perlík F. Frequency of single nukleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochem Funct 2008;26:76–81.10.1002/cbf.1402Search in Google Scholar PubMed
15. Slanar O, Drazd’áková M, Babiárová K, Pechandová K, Buzková H, Perlik F, et al. [Genotyping of CYP2D6 and CYP2C19]. Cas Lek Cesk 2007;146:708–11. (article in Czech).Search in Google Scholar
16. Slanar O, Dupal P, Matouskova O, Vondrackova H, Pafko P, Perlik F. Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. Bratisl Lek Listy 2012;113:152–5.10.4149/BLL_2012_036Search in Google Scholar
17. Pindurová E, Žourková A, Zrůstová J, Juřica J, Pavelka A. Alternative reliable method for cytochrome P450 2D6 poor metabolizers genotyping. Mol Biotechnol 2013;53:29–40.10.1007/s12033-012-9510-2Search in Google Scholar PubMed
18. Pechandová K, Buzková H, Slanar O, Perlík F. Polymorphisms of the MDR1 gene in the Czech population. Folia Biol (Praha) 2006;52:184–9.Search in Google Scholar
19. Matouskova O, Slanar O, Adamkova J, Pafko P, Perlik F, Adamek S. Impact of MDR1 genetic polymorphisms on postoperative piritramide analgesia. Bratisl Lek Listy 2013;114:133–5.10.4149/BLL_2013_029Search in Google Scholar
20. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 2008;86:1206–13.10.1097/TP.0b013e318187c4d1Search in Google Scholar PubMed
21. Pechandova K, Buzkova H, Matouskova O, Perlik F, Slanar O. Genetic polymorphisms of CYP2C8 in the Czech Republic. Genet Test Mol Biomarkers 2012;16:812–6.10.1089/gtmb.2011.0275Search in Google Scholar PubMed PubMed Central
22. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos 2003;31:687–90.10.1124/dmd.31.6.687Search in Google Scholar PubMed
23. Cífková R, Skodová Z, Bruthans J, Adámková V, Jozífová M, Galovcová M, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010;211:676–81.10.1016/j.atherosclerosis.2010.04.007Search in Google Scholar PubMed
24. Jurcikova L, Adamkova V, Lanska V, Suchanek P, Hubacek JA. Lack of association between variants within the AHSG, HRCT and NPY2R genes and anthropometrical parameters in Czech post MONICA study. Balk J Med Gen 2013;16:63–8.Search in Google Scholar
25. Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur J Clin Pharmacol 2010;66:571–8.10.1007/s00228-010-0785-6Search in Google Scholar
26. Milojkovic M, Stojnev S, Jovanovic I, Ljubisavljevic S, Stefanovic V, Sunder-Plassman R. Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. Pharmacol Rep 2011;63:808–14.10.1016/S1734-1140(11)70593-XSearch in Google Scholar
27. Brocic M, Supic G, Zeljic K, Jovic N, Kozomara R, Zagorac S, et al. Genetic polymorphisms of ADH1C and CYP2E1 and risk of oral squamous cell carcinoma. Otolaryngol Head Neck Surg 2011;145:586–93.10.1177/0194599811408778Search in Google Scholar PubMed
28. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59:303–12.10.1007/s00228-003-0606-2Search in Google Scholar PubMed
29. Makeeva O, Stepanov V, Puzyrev V, Goldstein DB, Grossman I. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolising enzymes. Pharmacogenomics 2008;9:847–68.10.2217/14622416.9.7.847Search in Google Scholar PubMed
30. Bozina N, Granić P, Lalić Z, Tramisak I, Lovrić M, Stavljenić-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 2003;44:425–8.Search in Google Scholar
31. Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine am ong patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1439–44.10.1016/j.pnpbp.2008.03.018Search in Google Scholar PubMed
32. Brinar M, Cukovic-Cavka S, Bozina N, Ravic KG, Markos P, Ladic A, et al. MDR1 polymorphisms are associated with inflammatory bowel disease in a cohort of Croatian IBD patients. BMC Gastroenterol 2013;13:57.10.1186/1471-230X-13-57Search in Google Scholar PubMed PubMed Central
33. Basic S, Hajnsek S, Bozina N, Filipcic I, Sporis D, Mislov D, et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 2008;17:524–30.10.1016/j.seizure.2008.01.003Search in Google Scholar PubMed
34. Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 2010;66:1109–17.10.1007/s00228-010-0850-1Search in Google Scholar PubMed
35. Luptáková L, Sivaková D, Šrámeková D, Cvíčelová M. The association of cytochrome P450 1B1 Leu432Val polymorphism with biological markers of health and menopausal symptoms in Slovak midlife women. Menopause 2012;19:216–24.10.1097/gme.0b013e3182281b54Search in Google Scholar PubMed
36. Krivulcik T, Sedlak J, Bartosova Z. Frequency of the three most common polymorphisms in the MDR1 gene in Slovak population. Neoplasma 2009;56:101–7.10.4149/neo_2009_02_101Search in Google Scholar PubMed
37. Saraeva RB, Paskaleva ID, Doncheva E, Eap CB, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. J Clin Pharm Ther 2007;32:641–9.10.1111/j.1365-2710.2007.00870.xSearch in Google Scholar PubMed
38. Petrova DT, Yaramov N, Toshev S, Nedeva P, Maslyankov S, von Ahsen N, et al. Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls. Onkologie 2007;30:559–63.Search in Google Scholar
39. Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, Atanasova S, et al. No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol 2008;134:317–22.10.1007/s00432-007-0279-9Search in Google Scholar PubMed
40. Dolzan V, Rudolf Z, Breskvar K. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis 1995;16:2675–8.10.1093/carcin/16.11.2675Search in Google Scholar PubMed
41. Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomsic M, Suput D, et al. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos 2009;37:2061–8.10.1124/dmd.109.027482Search in Google Scholar PubMed
42. Levkovich NN, Gorovenko NG, Myasoedov DV. Association of polymorphic G1934A variant (allele *4) of CYP2D6 gene with increased risk of breast cancer development in Ukrainian women. Exp Oncol 2011;33:136–9.Search in Google Scholar
43. Semiz S, Dujić T, Ostanek B, Prnjavorac B, Bego T, Malenica M, et al. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina. Med Glas (Zenica) 2011;8:84–9.Search in Google Scholar
44. Jaanson P, Marandi T, Kiivet RA, Vasar V, Vään S, Svensson JO, et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) 2002;162: 67–73.10.1007/s00213-002-1059-5Search in Google Scholar PubMed
45. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics od drug-metabolising enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013;13:1–11.10.1038/tpj.2012.45Search in Google Scholar PubMed
46. Turpeinen M, Zanger UM. Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metabol Drug Interact 2012;27:185–97.10.1515/dmdi-2012-0027Search in Google Scholar PubMed
47. Mitropoulos K, Johnson L, Vozikis A, Patrinos GP. Relevance of pharmacogenomics for developing countries in Europe. Drug Metabol Drug Interact 2011;26:143–6.10.1515/DMDI.2011.028Search in Google Scholar PubMed
©2014 by Walter de Gruyter Berlin Boston
